Sign inJoin waitlistJoin the waitlist

Marissa Just

Assistant Professor of Clinical Pediatrics · Indiana University School of Medicine

Credentials: · · ·

History

Indiana University School of Medicine
Present

Duke Children's Hospital
2025–2026
Pediatric Hematology/Oncology
Duke University Hospital
2022–2025
Pediatrics
University of Tennessee College of Medicine
2014–2017
Doctor of Medicine
2010–2014

Research

Receptor tyrosine kinase inhibitors for the treatment of osteosarcoma and Ewing sarcoma
Review · Pediatric Blood & Cancer · 2021 · First of 3 authors · 22 citations
Precision Medicine Highlights Dysregulation of the CDK4/6 Cell Cycle Regulatory Pathway in Pediatric, Adolescents and Young Adult Sarcomas
Review · Cancers · 2022 · 11 citations
Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Journal of the National Comprehensive Cancer Network · 2025 · 5 citations

Corinne Linardic
3 papers · 3 as a resident
BG
Brian Guedes
2 papers · 2 as a fellow
Christian Cerda-Smith
2 papers · 2 as a resident
Christopher Collier
2 papers · 2 as a fellow
Kimberly Stegmaier
2 papers
L Wurtz
2 papers
Leen Barbar
2 papers · 2 as a resident
Michael Ferguson
2 papers
Rex Bentley
2 papers
Aaron Weiss
1 paper
Ami Desai
1 paper
Amy Walz
1 paper

Clinical trials

A Study Comparing Higher Dose Chemotherapy Over a Shorter Amount of Time to Lower Dose Chemotherapy Plus Maintenance Over a Longer Amount of Time in Patients With Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma (IR RMS)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2026–2031
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2031
Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma
Site PI · Recruiting · Phase 3
Children's Oncology Group
2025–2029
A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)
Site PI · Recruiting · Phase 2
National Cancer Institute (NCI)
2024–2027